The closing price of Relay Therapeutics Inc (NASDAQ: RLAY) was $7.60 for the day, down -5.24% from the previous closing price of $8.02. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 862960 shares were traded.
Ratios:
Our analysis of RLAY’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 25.44 and its Current Ratio is at 25.44. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On April 19, 2023, Raymond James Upgraded its rating to Strong Buy which previously was Outperform but kept the price unchanged to $29.
On April 13, 2023, Raymond James started tracking the stock assigning a Outperform rating and target price of $29.Raymond James initiated its Outperform rating on April 13, 2023, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 27 ’24 when Bergstrom Donald A sold 765 shares for $7.70 per share. The transaction valued at 5,890 led to the insider holds 530,113 shares of the business.
Catinazzo Thomas sold 348 shares of RLAY for $2,680 on Mar 27 ’24. The Chief Financial Officer now owns 341,498 shares after completing the transaction at $7.70 per share. On Mar 27 ’24, another insider, Adams Brian, who serves as the Chief Legal Officer of the company, sold 348 shares for $7.70 each. As a result, the insider received 2,680 and left with 327,390 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 996.96M and an Enterprise Value of 300.34M. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.02 while its Price-to-Book (P/B) ratio in mrq is 1.29. Its current Enterprise Value per Revenue stands at 11.76 whereas that against EBITDA is -0.80.
Stock Price History:
Over the past 52 weeks, RLAY has reached a high of $19.23, while it has fallen to a 52-week low of $5.95. The 50-Day Moving Average of the stock is 9.29, while the 200-Day Moving Average is calculated to be 9.78.
Shares Statistics:
RLAY traded an average of 1.10M shares per day over the past three months and 1.16M shares per day over the past ten days. A total of 127.46M shares are outstanding, with a floating share count of 92.20M. Insiders hold about 29.71% of the company’s shares, while institutions hold 71.65% stake in the company. Shares short for RLAY as of Mar 15, 2024 were 11.81M with a Short Ratio of 10.74, compared to 9.81M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.00% and a Short% of Float of 11.59%.
Earnings Estimates
The firm’s stock currently is rated by 9 analysts. On average, analysts expect EPS of -$0.7 for the current quarter, with a high estimate of -$0.63 and a low estimate of -$0.81, while EPS last year was -$0.78. The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.64 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.44 and -$3.33 for the fiscal current year, implying an average EPS of -$2.92. EPS for the following year is -$2.78, with 9 analysts recommending between -$2.31 and -$3.11.
